CNS Lymphocytic Vasculitis in a Young Woman With COVID-19 Infection

Garrett M. Timmons, MD,* Torge Rempe, MD,* Elizabeth A. Bevins, MD, PhD, Vanessa Goodwill, MD, Annalise Miner, Arthur Kavanaugh, MD, Michele Ritter, MD, and Jennifer S. Graves, MD, PhD, MAS

Neurol Neuroimmunol Neuroinflamm 2021;8:e1048. doi:10.1212/NXI.0000000000001048

Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been associated with several neurologic manifestations including the development of cerebral lesions resembling CNS vasculitis in elderly patients with severe coronavirus disease 2019 (COVID-19).1–4 Here, we report additional evidence for COVID-19–related CNS vasculitis, confirmed by biopsy, in a young healthy patient with otherwise mild COVID-19 infection.

Case Report

A 26-year-old woman experienced 4 days of anosmia, dysgeusia, malaise, and fatigue 6 days after an airplane flight in mid-March 2020. Approximately 2–3 weeks later, she noticed difficulty keeping “flip-flops” on her left foot slowly progressing to dragging of her left foot in July 2020. Neurologic examination revealed left pyramidal tract dysfunction with left-sided weakness (4+/5 Medical Research Council Scale of left elbow flexion, hip flexion, knee flexion, and foot dorsiflexion) and hyperreflexia (3+ in biceps, brachioradialis, triceps, patellar, and Achilles reflexes with unsustained foot clonus and pathologic reflexes). The rest of her examination was normal, and she denied headache or any change in mental status or cognition.

Her initial brain MRI demonstrated multiple, irregular, peripherally enhancing lesions clustered within the right frontoparietal white matter. These lesions also had peripheral diffusion restriction and surrounding T2/fluid-attenuated inversion recovery hyperintensity suggestive of edema and internal susceptibility likely reflective of blood products (Figure, A, B, F, G). Cervical spine MRI was normal. CSF analysis showed a cell count of 1/mm³, protein level of 29 mg/dL, and glucose of 59 mg/dL. SARS-CoV-2 PCR testing was not available during the episode of presumed COVID-19 symptoms in March 2020 and was nonreactive in August 2020 during her initial hospitalization. SARS-CoV-2 antinucleocapsid antibody testing was significant for 2 positive test results (Roche assay) in September 2020, although she had negative results in simultaneously obtained additional serologic assays (Diazyme, Abbott; Figure, K). No SARS-CoV-2 PCR was performed in the CSF.

Evaluation in a COVID-19 infectious disease clinic resulted in confirmation of a prior COVID-19 infection by clinical criteria. Otherwise, extensive laboratory workup of the patient’s serum and CSF for other infectious, neoplastic, or autoimmune causes was negative.

Stereotactic biopsy of one of the right frontoparietal lesions demonstrated findings consistent with lymphocytic vasculitis, including infiltration of vessel walls by lymphocytes (predominantly CD3⁺ [mixture of CD4⁺ and CD8⁺] T cells with a sparse admixture of CD20⁺ B cells) with endothelial hypertrophy. In addition, edematous and gliotic white matter changes with extensive lymphoplasmacytic perivascular inflammation were noted, along with parenchymal necrosis and abundant dystrophic calcification. No viral inclusions were seen (Figure, L–V).

*These authors contributed equally to this work as co-first authors.

From the Department of Neurosciences (G.M.T., T.R., E.A.B., A.M., J.S.G.), University of California San Diego, School of Medicine; Department of Pathology (V.G.), Department of Rheumatology (A.K.), and Department of Infectious Diseases (M.R.), University of California San Diego, La Jolla; and Department of Neurology (T.R.), University of Florida, College of Medicine, Gainesville.

Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

The Article Processing Charge was funded by the authors.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
The patient was treated with IV methylprednisolone 1,000 mg daily for 3 days, followed by an oral prednisone taper over 6 months starting at 60 mg daily. After 2 months, mycophenolate mofetil was added and uptitrated over 3 weeks to 1,000 mg twice daily with a 4-month overlap with the ongoing prednisone taper. The patient showed continued clinical improvement of her left-sided hemiparesis with minimal residual left lower extremity weakness on most recent examination. Follow-up brain MRIs at 1, 3, and 6 months after initiation of corticosteroids showed continuing decrease in the size and intensity of the lesions. The patient also showed a decreased size of T2/FLAIR hyperintensities and decreased contrast enhancement. The time course and results of antinucleocapsid SARS-CoV-2 antibody testing showed a decrease in Roche titer levels from 1.03 to 0.7 with a solid black line marking the assay’s cutoff of 1.0. The initial and repeat MRI, biopsy, and initiation of corticosteroids are shown below the timeline. The histopathology showed edematous and gliotic white matter with extensive lymphoplasmacytic perivascular inflammation, as well as infiltration of vessel walls by lymphocytes, consistent with lymphocytic vasculitis. Multiple foci of eosinophilic coagulative necrosis with extensive dystrophic calcification were also noted. Stereotactic biopsy of the right frontal lesion showed focal endothelial swelling and hypertrophy, as well as vascular proliferation. Immunohistochemistry showed the perivascular and intravascular lymphocytes to be predominantly CD3-positive T cells (CD3 IHC, ×100) with a small subset of CD20-positive B cells (CD20 IHC, ×100). Numerous perivascular CD4-positive T lymphocytes (CD4 IHC, ×100), many perivascular and parenchymal CD8-positive T lymphocytes (CD8 IHC, ×100), abundant perivascular macrophages and parenchymal activated microglia (CD68 IHC, ×100), and scattered perivascular plasma cells (CD138 IHC, ×100) were observed.
Notably, all 4 previous cases demonstrating CNS vasculitis were diagnosed based solely on imaging findings with no biopsy confirmation. All 4 were older (aged 64–69 years), experienced a more severe COVID-19 infection requiring intensive care unit level care, and developed earlier severe manifestation of neurologic symptoms compared with our case.1,4

A possible underlying mechanism is an endotheliitis caused by direct SARS-CoV-2 infection of endothelial cells through binding to the angiotensin-converting enzyme 2 receptor, which has been shown in renal, gastrointestinal, pulmonal, and cerebral vasculature.5,6 Alternatively, a proinflammatory state may have unmasked a primary CNS vasculitis. Interesting differences between this case and typical primary CNS vasculitis include the lack of headache or alteration in mental status/cognition, although a variety of phenotypes can be seen in this condition. Regardless of the mechanism, our case demonstrates that young patients with mild COVID-19 infection are still at risk for neurologic complications. Further studies of long-term outcomes in similar cases are needed to optimize the choice and duration of immunosuppression.

**Discussion**

We report a case of biopsy-confirmed CNS vasculitis that shortly followed a COVID-19 infection. To our knowledge, this is the fifth reported case of COVID-19–related CNS vasculitis and the first to be confirmed by biopsy or to occur in a young patient with otherwise mild COVID-19 infection. As the patient’s slowly progressive neurologic deficit began 2–3 weeks after her COVID-19 infection, this temporal correlation suggests a causal relationship, although there remains diagnostic uncertainty as PCR testing was not performed during her acute infection.

Notably, all 4 previous cases demonstrating CNS vasculitis were diagnosed based solely on imaging findings with no biopsy confirmation. All 4 were older (aged 64–69 years), experienced a more severe COVID-19 infection requiring intensive care unit level care, and developed earlier severe manifestation of neurologic symptoms compared with our case.1,4

A possible underlying mechanism is an endotheliitis caused by direct SARS-CoV-2 infection of endothelial cells through binding to the angiotensin-converting enzyme 2 receptor, which has been shown in renal, gastrointestinal, pulmonal, and cerebral vasculature.5,6 Alternatively, a proinflammatory state may have unmasked a primary CNS vasculitis. Interesting differences between this case and typical primary CNS vasculitis include the lack of headache or alteration in mental status/cognition, although a variety of phenotypes can be seen in this condition. Regardless of the mechanism, our case demonstrates that young patients with mild COVID-19 infection are still at risk for neurologic complications. Further studies of long-term outcomes in similar cases are needed to optimize the choice and duration of immunosuppression.

**Acknowledgment**

The authors thank the UC San Diego Neuropathology Division Fund for making possible the immunohistologic stains included in this article.

**Study Funding**

The authors report no targeted funding.

**Disclosure**

The authors declare that they have no competing interests. Unrelated to the work, the authors declare the following: G.M. Timmons reports no disclosures relevant to the manuscript. T. Rempe receives grant funding from the National MS Society. E.A. Bevins, V. Goodwill, and A. Miner report no disclosures relevant to the manuscript. A. Kavanaugh conducted research sponsored by AbbVie, Amgen, Eli Lilly, Novartis, and Pfizer. M. Ritter reports no disclosures relevant to the manuscript. J.S. Graves over the past year has grant/contract research support from the National MS Society, Biogen, and Octave Bioscience. She serves on a steering committee for a trial supported by Novartis; she has received honoraria for a nonpromotional, educational activity for Sanofi-Genzyme; and she has received speaker fees from Alexion and BMS and served on an advisory board for Genentech. Go to Neurology.org/NN for full disclosures.

**Publication History**

Received by *Neurology: Neuroimmunology & Neuroinflammation* March 12, 2021. Accepted in final form June 3, 2021.


CNS Lymphocytic Vasculitis in a Young Woman With COVID-19 Infection
Garrett M. Timmons, Torge Rempe, Elizabeth A. Bevins, et al.
Neurol Neuroimmunol Neuroinflamm 2021;8;
DOI 10.1212/NXI.0000000000001048

This information is current as of July 28, 2021

<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>including high resolution figures, can be found at: <a href="http://nn.neurology.org/content/8/5/e1048.full.html">http://nn.neurology.org/content/8/5/e1048.full.html</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>References</td>
<td>This article cites 6 articles, 2 of which you can access for free at: <a href="http://nn.neurology.org/content/8/5/e1048.full.html##ref-list-1">http://nn.neurology.org/content/8/5/e1048.full.html##ref-list-1</a></td>
</tr>
<tr>
<td>Subspecialty Collections</td>
<td>This article, along with others on similar topics, appears in the following collection(s): Autoimmune diseases <a href="http://nn.neurology.org/cgi/collection/autoimmune_diseases">http://nn.neurology.org/cgi/collection/autoimmune_diseases</a> COVID-19 <a href="http://nn.neurology.org/cgi/collection/covid_19">http://nn.neurology.org/cgi/collection/covid_19</a> Post-infectious <a href="http://nn.neurology.org/cgi/collection/postinfectious_Vasculitis">http://nn.neurology.org/cgi/collection/postinfectious_Vasculitis</a> <a href="http://nn.neurology.org/cgi/collection/vasculitis">http://nn.neurology.org/cgi/collection/vasculitis</a></td>
</tr>
<tr>
<td>Permissions &amp; Licensing</td>
<td>Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at: <a href="http://nn.neurology.org/misc/about.xhtml#permissions">http://nn.neurology.org/misc/about.xhtml#permissions</a></td>
</tr>
<tr>
<td>Reprints</td>
<td>Information about ordering reprints can be found online: <a href="http://nn.neurology.org/misc/addir.xhtml#reprintsus">http://nn.neurology.org/misc/addir.xhtml#reprintsus</a></td>
</tr>
</tbody>
</table>

Neurol Neuroimmunol Neuroinflamm is an official journal of the American Academy of Neurology. Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.. All rights reserved. Online ISSN: 2332-7812.